WS #16350
Amid the volatility in tech and energy, defensive consumer staples are outperforming. Procter & Gamble has reached a 52-week high, signaling a flight to safety among institutional investors. Additionally, PepsiCo saw its largest-ever insider buy of $23.7 million by Director Robert Pohlad, providing a bullish signal for the stock despite the challenging macro environment of rising input costs. Moderna shares have collapsed by 20% following the leak of disappointing clinical data for its cancer vaccine candidate. The negative sentiment is so strong that options traders are aggressively selling puts, betting on further downside or stagnation. This event is isolated to the biotech sector and does not appear to be impacting the broader healthcare index, but it serves as a cautionary tale for speculative biotech valuations.
Defensive Rotation
Amid the volatility in tech and energy, defensive consumer staples are outperforming. Procter & Gamble has reached a 52-week high, signaling a flight to safety among institutional investors. Additionally, PepsiCo saw its largest-ever insider buy of $23.7 million by Director Robert Pohlad, providing a bullish signal for the stock despite the challenging macro environment of rising input costs.
Moderna shares have collapsed by 20% following the leak of disappointing clinical data for its cancer vaccine candidate. The negative sentiment is so strong that options traders are aggressively selling puts, betting on further downside or stagnation. This event is isolated to the biotech sector and does not appear to be impacting the broader healthcare index, but it serves as a cautionary tale for speculative biotech valuations.